Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).
Publication
, Conference
Hamilton, EP; Kimmick, GG; Desai, N; Singh, S; Hopkins, JO; Marcom, PK; Chadaram, V; Welch, R; Trieu, VN; Blackwell, KL
Published in: Journal of Clinical Oncology
May 20, 2010
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
1109 / 1109
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hamilton, E. P., Kimmick, G. G., Desai, N., Singh, S., Hopkins, J. O., Marcom, P. K., … Blackwell, K. L. (2010). Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). In Journal of Clinical Oncology (Vol. 28, pp. 1109–1109). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.1109
Hamilton, E. P., G. G. Kimmick, N. Desai, S. Singh, J. O. Hopkins, P. K. Marcom, V. Chadaram, R. Welch, V. N. Trieu, and K. L. Blackwell. “Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).” In Journal of Clinical Oncology, 28:1109–1109. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.1109.
Hamilton EP, Kimmick GG, Desai N, Singh S, Hopkins JO, Marcom PK, et al. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 1109–1109.
Hamilton, E. P., et al. “Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 1109–1109. Crossref, doi:10.1200/jco.2010.28.15_suppl.1109.
Hamilton EP, Kimmick GG, Desai N, Singh S, Hopkins JO, Marcom PK, Chadaram V, Welch R, Trieu VN, Blackwell KL. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 1109–1109.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
1109 / 1109
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences